Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocysti...
Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
According to EORTC/MSGERC diagnostic criteria, we observed that the use of steroids was the most frequent host factor that predispose to PJP [4]. [...]Razazi et al. showed that the two proven PJP diagnosis in NC-ARDS cohort had Beta-D Glucan assay (BDG) > 80, while in our experience we documented negative BDG in all the proven cases. [...]we think...
Alternative Titles
Full title
Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4825f3c05ca946699981dc588d8a1901
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4825f3c05ca946699981dc588d8a1901
Other Identifiers
ISSN
1364-8535
E-ISSN
1364-8535,1466-609X,1366-609X
DOI
10.1186/s13054-021-03836-7
